Raymond James Financial’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
Other funds holding VRDN
Raymond James Financial's VRDN Position: Q3 2026 in Review
Raymond James Financial opened a new position in Viridian Therapeutics (VRDN) in Q3 2026: 71,260 shares worth $1.47M. The stake represents ﹤0.01% of the portfolio and ranks #3751 among its holdings. This is a return to the name: Raymond James Financial previously reported a position in VRDN as recently as Q1 2026.
Raymond James Financial first reported a position in VRDN in Q4 2024 and has held it in 7 quarters since. The position peaked at $9.42M in Q4 2025. 154 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.
- Raymond James Financial held 71,260 shares of Viridian Therapeutics worth $1.47M as of Q3 2026.
- Viridian Therapeutics was a new Raymond James Financial position in Q3 2026.
- Viridian Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #3751 holding.
- Raymond James Financial first reported a position in Viridian Therapeutics in Q4 2024 and has held it in 7 quarters since.
- Raymond James Financial's Viridian Therapeutics position peaked at $9.42M in Q4 2025.
- 154 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.
Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.